# Definium Therapeutics, Inc. (DFTX) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Definium Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/DFTX/mda/fy2025/): filed 2026-02-26; accession 0001193125-26-076742 (https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/DFTX/mda/fy2024/): filed 2025-03-06; accession 0000950170-25-034176 (https://www.sec.gov/Archives/edgar/data/1813814/000095017025034176/mnmd-20241231.htm)
- [FY 2023 MD&A](/company/DFTX/mda/fy2023/): filed 2024-02-28; accession 0000950170-24-021656 (https://www.sec.gov/Archives/edgar/data/1813814/000095017024021656/mnmd-20231231.htm)
- [FY 2022 MD&A](/company/DFTX/mda/fy2022/): filed 2023-03-09; accession 0000950170-23-007053 (https://www.sec.gov/Archives/edgar/data/1813814/000095017023007053/mnmd-20221231.htm)
- [FY 2021 MD&A](/company/DFTX/mda/fy2021/): filed 2022-03-28; accession 0000950170-22-004724 (https://www.sec.gov/Archives/edgar/data/1813814/000095017022004724/mnmd-20211231.htm)

Back to /company/DFTX/